# Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

> **NCT01846390** · PHASE1 · COMPLETED · sponsor: **Canadian Cancer Trials Group** · enrollment: 21 (actual)

## Conditions studied

- Peripheral T-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Dexamethasone
- **DRUG:** Cisplatin
- **DRUG:** Romidepsin

## Key facts

- **NCT ID:** NCT01846390
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-01
- **Primary completion:** 2016-07-06
- **Final completion:** 2018-09-19
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01846390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01846390, "Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01846390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*